51¸£Àû

Accelerate safe gene editing drug discovery with INDUCE-seq® screening.

51¸£Àû INDUCE-seq® offers a high-throughput, PCR-free, single-nucleotide resolution platform, enabling developers to precisely quantify on-target editing efficiency, compare guide RNAs, and eliminate candidates with off-target effects early in the screening phase. Compatible with primary human cells, T cells, and iPSCs, this unbiased approach empowers informed candidate selection with faster turnaround and reduced downstream risk, boosting confidence as you move toward preclinical and clinical milestones.

In the early discovery and screening phase of drug development, INDUCE-seq can be offered in a higher throughput option for:

• Quantify on-target editing efficiency across different cell types, including primary human cells, T cells, and iPSCs, enabling favorable selection of candidates.
• Guide development: Look at on and off target gene editing activity to compare guide RNAs.
• Detect and eliminate drug candidates with off-target effects early in development, improving the safety profile of lead candidates and reducing costly downstream failures.
• Characterize and screen novel gene editing nucleases using single-nucleotide resolution readout of break end structure. 
• Compare multiple editing approaches side-by-side to identify the most precise and effective gene-editing strategies for a given therapeutic target and identify non-productive guides early.

This dual capability makes INDUCE-seq an essential tool for derisking gene-edited therapeutics, accelerating preclinical development, and building confidence in the safety efficiency of drug candidates headed for the clinic.

INDUCE-seq® Offering

INDUCE-seq®, rapid, high-resolution detection of double-stranded breaks (DSBs) is now available as an in-lab solution, giving developers maximum control over timelines and experimental design, as well as in the traditional full-service model.